You are here

P&T News

January 9

Researchers collaborated to study the effect of advances in screening and treatment
Replacing daily pills with a weekly regimen could help patients adhere to therapy

January 8

Medication used as monotherapy for high-risk cases
Getting the shot every year was about twice as effective
Drug previously limited to those with solid tumors

January 4

So-called “association plans” would be cheaper but cover less
The industry expected the gene therapy for a rare form of blindness to cost $1 million
Atcell is derived from adipose and meant for autologous use

January 2

But average returns on research and development have fallen
The mechanism of action is not fully understood, but additional trials are indicated

December 28

Valsartan was first FDA-approved in 2001 as Diovan tablets
Brand-name Reyataz (Bristol-Myers Squibb) generated annual sales of more than $400 million in 2017
The minimally invasive technology is a synthetic, resorbable bone-graft substitute

December 26

An SGLT2 inhibitor and two fixed-dose combinations will be available in January and February 2018
The noninvasive technology is used in conjunction with breast-conserving treatment
Agent increases BP in adults with septic or other distributive shock

December 21

FDA announces that four studies showed no increased risk of death
Accelerated approval for neoadjuvant use also converted to full approval
Recurrence-free survival superior to Yervoy in trial

Pages